title: Reversible tacrolimus-induced neurotoxicity isolated to the brain stem.
abstract: Diplopia, nystagmus, visual hallucinations, and internuclear ophthalmoplegia developed in a 30-year-old woman 84 days after she received a matched, unrelated bone marrow transplant for chronic myeloid leukemia. A regimen of tacrolimus had been administered since the transplantation was performed. MR imaging revealed bilaterally symmetric regions of signal abnormality with abnormal contrast enhancement in the brain stem. No supratentorial abnormality was present. Tacrolimus therapy was discontinued, and the symptoms resolved. MR imaging that was performed 10 days after tacrolimus was discontinued showed resolution of the abnormalities.
authors.affiliation: Department of Radiology, Georgetown University Medical Center, Washington, DC, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Oliverio
authors.forename: L
authors.initials: L
authors.lastname: Restrepo
authors.forename: S A
authors.initials: SA
authors.lastname: Mitchell
authors.forename: C S
authors.initials: CS
authors.lastname: Tornatore
authors.forename: S R
authors.initials: SR
authors.lastname: Frankel
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D001933:Brain Stem / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D020258:Neurotoxicity Syndromes / Q000175:diagnosis / Q000209:etiology*; D012075:Remission, Spontaneous; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus